Press Releases

Funding for Manufacturing and for Brain Cancer Trial At 30 Sites In Germany Bethesda, Maryland, May 1, 2012 – Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (NW Bio) today announced that, working together with the Fraunhofer Institute (IZI), it has received approval of a major grant from the Sächsische Aufbau Bank (SAB or Saxony Development Bank) in Germany. The grant will reimburse fifty percent (50%) of the costs for... Read More

After 13 Months of Complex Processes, DCVax®-L Program Poised To Proceed In Germany Bethesda, Maryland, April 24, 2012 – Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (NW Bio) joined the Fraunhofer IZI Institute in announcing that, working closely together over the course of more than 13 months, the parties have completed significant milestones in NW Bio’s DCVax®-L program for brain cancer in Germany. As a result, the... Read More

Dr. Navid Malik and Mr. Jerry Jasinowski Bring Extensive Experience to the Board Bethesda, Maryland, April 17, 2012 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio), a biotech company developing DCVax® personalized immune therapies for cancer, is pleased to announce the addition of Dr. Navid Malik and Mr. Jerry Jasinowski to the Company’s Board of Directors. These new members bring to the NW Bio Board longstanding, deep... Read More

Programs Include Both Clinical Trial and Compassionate Use Bethesda, Maryland, April 12, 2012 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) (NW Bio) announced today that it is partnering with King’s Health Partners to both manufacture and deliver a new treatment for patients with brain cancer as part of its ongoing 240-patient clinical trial for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. Specialists... Read More

COO Dr. Anthony Maida To Discuss “Industry Innovators Blazing The Trail Towards Successful and Sustained Commercialization” BETHESDA, MD, February 29, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that its COO, Anthony Maida III, Ph.D., MA, MBA, will be presenting at the Cancer Immunotherapy Conference as the lead afternoon speaker at 1:45 pm on Wednesday, February 29, 2012, in Boston,... Read More